Stridebio Inc. landed a collaboration and license agreement with Takeda Pharmaceutical Co. Ltd. to develop in vivo adeno-associated virus- (AAV) based therapies for three targets, including Friedreich's ataxia (FA). Stridebio is eligible to receive about $680 million in future development and commercial milestones from Takeda, plus royalties on global net sales of commercial products the collaboration produces. Read More
HONG KONG – Chinese drugmaker Luye Pharma Group Ltd. said it filed an NDA submission to the U.S. FDA for Rykindo, its novel risperidone extended-release microsphere for injection, to treat schizophrenia and bipolar disorder. It could become the first innovative drug developed by China to get marketing clearance in the U.S. Read More
HONG KONG – Asian drugmakers are increasingly embracing the artificial intelligence (AI) technology for drug discovery. The latest example is Japanese drug developer Ono Pharmaceutical Co. Ltd., which recently entered a partnership with U.S. AI-backed biotech firm Twoxar Inc. Read More
HYDERABAD, India – India has modified its rules to allow the government to waive clinical trials for some new drugs that are approved and marketed in countries specified by India's apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO). Read More
Korean bioengineers and neurosurgeons have developed a novel patient-specific bioprinted tumor-on-a-chip model of glioblastoma, which might prove useful for identifying optimal treatments for patients resistant to standard first-line therapies. Read More
SHANGHAI – At this year's China Healthcare Investment Conference, the most insistent voices were not Chinese but American. Three speakers – a former U.S. federal judge, a leading biotech entrepreneur and a China pharma executive – each made their case for China's biopharma industry to have more influence, not just in China but globally. Read More
Alphanavi Pharma Co. Ltd., of Kyoto, Japan, was established by 1Kyoto University Innovation Capital Co. Ltd., also of Kyoto, and Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, with an investment of ¥900 million (US$8.1 million) as a carve-out business venture from Sumitomo Dainippon. Read More
